Diabetes mellitus tipo 2 y su nueva terapia farmacológica y no farmacológica, revisión de la bibliografía.
DOI:
https://doi.org/10.56048/MQR20225.7.3.2023.1959-1978Palabras clave:
Diabetes Mellitus tipo 2, Antidiabéticos, Control glucémico, Terapia farmacológica, Terapia no farmacológicaResumen
Introducción: La diabetes tipo 2 (DM2) se trata de una afección crónica que impacta a una creciente proporción de la población global. La gestión adecuada es esencial para prevenir complicaciones severas, incluyendo enfermedad cardiovascular y daño renal. Objetivo: Este artículo analiza la literatura actual sobre las novedosas terapias medicamentosas y no medicamentosas para tratar la DM2. Metodología: Se desarrolló una investigación bibliográfica exhaustiva, utilizando varias plataformas de datos académicas para identificar estudios y ensayos recientes que exploran las nuevas terapias farmacológicas y no farmacológicas para la DM2.
Resultados: Se identificaron varias nuevas terapias farmacológicas, incluyendo nuevos agentes hipoglucemiantes, así como enfoques no farmacológicos que incluyen cambios dietéticos, ejercicio y cambios del estilo de vida. Aunque la efectividad de estos tratamientos varió, se encontró que varios mejoraron el control glucémico y redujeron el riesgo de efectos negativos. Además, algunos tratamientos mostraron beneficios para bajar de peso y mejorar los factores de riesgo cardiovasculares. Conclusiones: Las nuevas intervenciones farmacéuticas y no farmacéuticas para la DM2 pueden proporcionar opciones de tratamiento adicionales y efectivas para los pacientes. Sin embargo, es esencial una evaluación individualizada para decidir el tratamiento más idóneo para cada individuo basado en su perfil clínico y sus preferencias. Para establecer la efectividad y la seguridad a largo plazo, los hallazgos también implican que se requiere más investigaciones de estas nuevas terapias, así como sus nuevas opciones terapéuticas.
Descargas
Métricas
Cited
DOI: 10.56048
Citas
Alberti KG, Eckel RH, Grundy SM, et al. (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120(16), 1640-1645.
American Diabetes Association. (2020). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care, 43(Supplement 1), S14–S31.
American Diabetes Association. (2020). 5. Lifestyle Management: Standards of Medical Care in Diabetes-2020. Diabetes Care, 43(Supplement 1), S66-S76.
American Diabetes Association. (2020). Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers. Clinical Diabetes, 38(1), 10-38.
American Diabetes Association. (2021). Standards of Medical Care in Diabetes—2021. Diabetes Care, 44(Supplement 1), S1-S232.
American Diabetes Association. (2022). Management of type 2 diabetes in adults: Standards of medical care in diabetes—2022. Diabetes Care, 45(Supplement 1), S15-S84.
American Diabetes Association. (2022). Standards of medical care in diabetes. Diabetes Care, 45(Supplement 1), S1-S157.
Buzzetti R, Zampetti S, Maddaloni E. (2017). Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 13(11), 674-686.
Carrillo-Larco RM, Bernabé-Ortiz A, Pillay TD, et al. (2016). Obesity risk in rural, urban and rural-to-urban migrants: prospective results of the PERU MIGRANT study. Int J Obes (Lond). 40(1), 181-185.
Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report, 2022. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
Colberg SR, Sigal RJ, Yardley JE, et al. (2016). Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care, 39(11), 2065-2079.
Contreras, I., Vehi, J., & de Leiva, A. (2022). Telemedicine for Diabetes Care: an Effective Tool for Diabetes Self-Management. Current Diabetes Reports, 22(1), 1-13.
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., ... & Buse, J. B. (2022). Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(1), 254-284.
Deacon, C. F. (2019). Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review. Diabetes, Obesity and Metabolism, 13(1), 7-18.
DeFronzo, R. A., Ferrannini, E., & Groop, L. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 1, 15019.
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., Saslow, L., Uelmen, S., Urbanski, P. B., & Yancy, W. S. (2019). Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care, 42(5), 731-754.
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., ... & Yancy, W. S. (2020). Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care, 43(5), 731-754.
Forouhi NG, Luan J, Hennings S, Wareham NJ. (2014). Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabetic Medicine, 24(2), 200-207.
Forouhi NG, Wareham NJ. (2014). Epidemiology of diabetes. Medicine (Abingdon), 42(12), 698-702.
Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation Research, 107(9), 1058–1070.
Ginsberg, H. N. (2019). Insulin resistance and cardiovascular disease. Journal of Clinical Investigation, 106(4), 453–458.
Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. (1991). Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 325(3), 147-152.
Imamura F, O'Connor L, Ye Z, et al. (2015). Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ, 351, h3576.
International Diabetes Federation. (2022). Diabetes Atlas 10th edition. Brussels: International Diabetes Federation.
Kahn SE, Cooper ME, Del Prato S. (2014). Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, 383(9922), 1068-1083.
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergstrom, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Backhed, F. (2013). Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature, 498(7452), 99–103.
Khunti, K., Gomes, M. B., Pocock, S., Shestakova, M. V., Pintat, S., Fenici, P., ... & Medina, J. (2020). Therapeutic Inertia in the Treatment of Hyperglycaemia in Patients with Type 2 Diabetes: A Systematic Review. Diabetes, Obesity and Metabolism, 20(2), 427-437.
Knowler WC, Barrett-Connor E, Fowler SE, et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346(6), 393-403.
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., McMurray, J. J. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology, 7(10), 776-785.
McCarthy, M. I. (2022). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated with Altered Short‐ and Long‐term Glycemic Response to DPP‐4 Inhibitor Therapy. Diabetes Care, 45(3), 599-605.
National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Diabetes. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health.
National Institutes of Health. (2022). Diabetes. National Institute of Diabetes and Digestive and Kidney Diseases website. Retrieved from https://www.niddk.nih.gov/health-information/diabetes
Patterson, R. E., Sears, D. D., & Horne, B. D. (2023). Metabolic Effects of Intermittent Fasting. Annual Review of Nutrition, 43, 371-393.
Pernicova, I., & Korbonits, M. (2014). Metformin—mode of action and clinical implications for diabetes and cancer. Nature Reviews Endocrinology, 10(3), 143-156.
Pouwer, F., Kupper, N., & Adriaanse, M. C. (2019). Does Emotional Stress Cause Type 2 Diabetes Mellitus? A Review from the European Depression in Diabetes (EDID) Research Consortium. Discovery Medicine, 9(45), 112-118.
Powers, M. A., Bardsley, J., Cypress, M., Duker, P., Funnell, M. M., Fischl, A. H., Maryniuk, M. D., Siminerio, L., & Vivian, E. (2017). Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care, 40(7), 964-970.
Prasad, R. B., & Groop, L. (2015). Genetics of type 2 diabetes—pitfalls and possibilities. Genes, 6(1), 87–123.
Prentki, M., & Nolan, C. J. (2006). Islet β cell failure in type 2 diabetes. Journal of Clinical Investigation, 116(7), 1802–1812.
Robertson, R. P., Harmon, J., Tran, P. O., & Poitout, V. (2004). Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes, 53(Supplement 1), S119–S124.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016). Pancreatic regulation of glucose homeostasis. Experimental & Molecular Medicine, 48(3), e219–e219.
Rubino F, Nathan DM, Eckel RH, et al. (2016). Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care, 39(6), 861-877.
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., Amiel, S. A., Kaplan, L. M., Taroncher-Oldenburg, G., & Cummings, D. E. (2020). Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care, 43(4), 753-760.
Samuel, V. T., & Shulman, G. I. (2016). The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. Journal of Clinical Investigation, 126(1), 12–22.
Schargrodsky H, Hernández-Hernández R, Champagne BM, et al. (2008). CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med. 121(1), 58-65.
Solomon SD, Chew E, Duh EJ, et al. (2018). Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care, 41(3), 412-418.
Spanakis EK, Golden SH. (2013). Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep. 13(6), 814-823.
Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. (2012). Prediabetes: a high-risk state for diabetes development. Lancet, 379(9833), 2279-2290.
Tilg, H., & Moschen, A. R. (2014). Microbiota and diabetes: an evolving relationship. Gut, 63(9), 1513–1521.
Tomita, T. (2016). Apoptosis in pancreatic β-islet cells in Type 2 diabetes. Bosnian Journal of Basic Medical Sciences, 16(3), 162–179.
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015). GLP-1 receptor agonists: a review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 6(1), 19-28.
Unger, R. H., & Zhou, Y. T. (2001). Lipotoxicity of β-Cells in Obesity and in Other Causes of Fatty Acid Spillover. Diabetes, 50(Supplement 1), S118–S121.
Wanner, C., Inzucchi, S. E., & Zinman, B. (2021). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. The New England Journal of Medicine, 375(4), 323-334.
Weir, G. C., & Bonner-Weir, S. (2013). Islet β cell mass in diabetes and how it relates to function, birth, and death. Annals of the New York Academy of Sciences, 1281(1), 92–105.
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Bansilal, S., Bhatt, D. L., Leiter, L. A., & McGuire, D. K. (2019). The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. American Heart Journal, 200, 83-89.
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., & Bhatt, D. L. (2019). Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation, 139(17), 2022-2031.
Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. (2014). Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2(1), 56-64.
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., ... & Johansen, O. E. (2021). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine, 373(22), 2117-2128
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 MQRInvestigar
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
®
Los autores se comprometen a respetar la información académica de otros autores, y a ceder los derechos de autor a la Revista MQRInvestigar, para que el artículo pueda ser editado, publicado y distribuido. El contenido de los artículos científicos y de las publicaciones que aparecen en la revista es responsabilidad exclusiva de sus autores. La distribución de los artículos publicados se realiza bajo una licencia 
